Table 1.

Studies Included in the Analysis

Disease	Studies*
DPN	1008-01440; 1008-02941; 1008-04042; 1008-13143; 1008-14944; 1008-15525; 1008-173; A0081030 (NCT00156078); A0081037 (NCT00141219)45; A0081060 (NCT00159679)24; A0081071 (NCT00143156); A0081081 (NCT00301223)46; A0081163 (NCT00553475)47
PHN	1008-03J; 1008-03042; 1008-04548; 1008-12749; 1008-132; 1008-15525; 1008-19650; A0081004 (NCT00159666)26; A0081081 (NCT00301223)46; A0081120 (NCT00394901)51; A6061026 (NCT00288652); A0081037 (NCT00141219)45
CLBP	1008-032; 1008-104
HIV neuropathy	A0081066 (NCT00232141)52; A0081244 (NCT01049217)
Cancer NeP	A0081124 (NCT00380874)53; A0081128 (NCT00381095)54
PT	A0081037 (NCT00141219)45; A0081064 (NCT00292188)28
Other NeP	1008-04J; 1008-160

DPN, diabetic peripheral neuropathy; PHN, postherpetic neuralgia; CLBP, chronic lower back pain; HIV, human immunodeficiency virus; NeP, neuropathic pain; PT, post-traumatic peripheral neuropathic pain.

^*Some studies were conducted across multiple diseases and appear under more than 1 disease heading. ClinicalTrials.gov identifying numbers shown where available (some historical trials are not recorded at ClinicalTrials.gov). CLBP studies included patients with nonspecific chronic lower back pain; no steps were taken to diagnose or characterize NeP. Cancer NeP includes studies in chemotherapy-induced neuropathy and cancer-induced bone pain. Other NeP includes studies in idiopathic trigeminal neuralgia and disturbed sleep concurrent with NeP.